Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  acalabrutinib
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-006, NCI-2015-01966, NCT02477696
Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-007, NCI-2015-02261, NCT02475681
ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-001, NCI-2014-00263, NCT02029443
ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-LY-001, NCI-2015-00533, NCT02328014
ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-209, NCI-2016-00105, NCT02586857
Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-007, NCI-2015-01131, NCT02448303
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-006, NCI-2015-01085, NCT02454179
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-208, NCI-2015-02121, NCT02537444
An Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-003, NCI-2014-02238, NCT02180711
Start Over